A Technology-Rich Pharmaceutical Company
Specialising in improving upon existing drugs which are off patent

Core Products

Future Products


Morvus Technology Limited, registered in England and Wales Company Number 5115093 Registered Office: Llanvetherine Court, Llanvetherine, Monmouthshire, NP7 8NL, is a pharmaceutical company specialising in the development and commercialisation of novel drugs for the oncology market. The Company is technology-rich and has the capability to generate revenue by out-licensing early-stage products whilst simultaneously progressing selected candidates through clinical development and into patient trials.

The Corporate aim of the Company is to ready the Morvus Technology products for ‘exit’ either individually or collectively from 2019 or earlier if circumstances, by way of corporate purchase of the various products, permit.

Professor Michael G Wyllie

Non-Executive Chairman

Prof Wyllie, Director and Founder of Global Pharma Consulting, is a graduate of the University of Aberdeen. He has over 30 years of experience in senior management positions in the pharmaceutical industry. While Director at Pfizer he was involved in the discovery, filing of intellectual property, development, regulatory filing and marketing of eight major pharmaceutical products including, amlodipine (Norvasc), doxazosin (Cardura), darifenacin (Enablex), fluconazole (Diflucan) sertaline (Zoloft) and sildenafil (Viagra). Subsequently, he has been involved in founding and successfully funding several ‘start up’ companies and the listing of four of these on the London Stock Market.

He is founder and CSO of Plethora Solutions Plc (AIM:PLE) which has a product, PSD502, undergoing regulatory review in the EU for premature ejaculation and which has been out-licensed to a major pharmaceutical company. He is Chairman of Glycomar Ltd, the Oban-based marine biotechnology company and a non- executive director of Repros Therapeutics (NASDAQ:RPRX) and Xion Inc. He is a founder member of both the International Advisory Board and Commercial Advisory Panel for Strathclyde University in Glasgow.

< Back to Board of Directors

Jonathan Beatson-Hird

Chief Executive

Jonathan has 26 years’ experience in both Emerging Companies and Emerging Markets. His core expertise is in equities, covering research, sales and corporate finance, predominantly as Managing Director of Deutsche Bank and Barings in New York. He co-founded Sarum Partners with Prof Tony Atkinson to take advantage of the once in a lifetime opportunity of investing in the oncology sector due to the revolution in the understanding of the dynamics of cancer and how it is best treated.

< Back to Board of Directors


Oliver de Giorgio Miller

Chief Operating Officer

Oliver has a wealth of experience in the management and commercial advancement of life science companies. He has worked for over 30 years with several global pharmaceutical and medical device companies including Schering AG, Hoffman la Roche, Intavent-Orthofix and Photo Therapeutics, a Cancer Research UK company and he has extensive experience advising a number of other early stage biopharmaceutical and medical device companies.

Since 2002 Oliver has worked as a life sciences analyst in the City, working alongside corporate finance, investor relations and sales teams on a wide range of transactions including IPOs, secondary issues and M & As. He is a director and investment manager of offshore fund, Sarum Investment (SICAV) plc, which is exclusively focused on the oncology sector.

< Back to Board of Directors

Mr David Baynes

Non-Executive Director

David was appointed as a non-executive director in September 2010. He is the Chief Executive and co-founder of Fusion IP plc, a company that owns the rights to 100% of university-owned research generated at two of the UK’s leading universities. The University of Sheffield and Cardiff University and has partnerships with two others Nottingham University and Swansea University. David has a wealth of commercial experience having previously worked at Celsis International plc (“Celsis”) from its incorporation to its flotation on the full list of the London Stock Exchange in July 1993 and Toad plc (now TG21 plc), which he also co-founded and was also responsible for taking from start-up to a full listing on the LSE.

< Back to Board of Directors

Sir Roger Jones OBE

Non-Executive Director

Sir Roger is a specialist in the economics of pharmaceutical development. He is a former Chairman of the Welsh Development Agency and a Governor of the BBC and worked for Wellcome Foundation Ltd before founding Penn Pharmaceuticals Ltd which has been a leading provider of fully integrated and cost effective pharma development outsourcing services. He also founded Lansdale Pharmacies, Alzeim and Zoobiotics. He was awarded an OBE in 1996 for services to the Pharmaceutical Industry and Knighted in the 2005 New Years Honours.

< Back to Board of Directors

Shareholders & Investors